奥贝胆酸治疗熊去氧胆酸应答不佳原发性胆汁性胆管炎的真实世界研究
该研究为西班牙和葡萄牙18家中心的前瞻性多中心真实世界研究,纳入120例不符合Paris II标准的原发性胆汁性胆管炎患者,评估奥贝胆酸(OCA)的有效性和安全性。78例完成至少1年OCA治疗,GLOBE评分显著下降0.17(95%CI 0.05-0.28;P=0.005),碱性磷酸酶显著下降81.3 U/L(95%CI 42.5-120;P<0.001),29.5%达到POISE应答,不良事件率35%,11.67%停药。
要点
- OCA可显著改善UDCA应答不佳PBC患者的GLOBE预后评分和碱性磷酸酶水平
- 真实世界中29.5%患者达到POISE应答标准,不良事件率35%,8.3%因瘙痒停药
- FIB-4和APRI保持稳定,提示肝纤维化无显著进展
核心结论
- 本研究支持III期试验数据,OCA治疗可显著改善PBC-Globe连续预后标志物评分且耐受性良好。
研究设计与样本
- 开放标签、前瞻性、真实世界、多中心研究,纳入西班牙和葡萄牙18家中心的连续不符合Paris II标准的PBC患者,共120例符合条件。
- 患者中位PBC诊断时间9.3年(4.0-13.8),21.7%有肝硬化,26.7%曾接受或同时接受贝特类治疗,78例完成至少1年OCA治疗。
主要发现
- GLOBE-PBC评分下降0.17(95%CI 0.05-0.28;P=0.005),UK-PBC评分下降0.81(95%CI -0.19-1.80;P=0.11)。
- 碱性磷酸酶下降81.3 U/L(95%CI 42.5-120;P<0.001),ALT下降22.1 U/L(95%CI 10.4-33.8;P<0.001),胆红素下降0.12 mg/dL(95%CI 0-0.24;P=0.044)。
- FIB-4和APRI保持稳定,按POISE标准29.5%(23/78)达到应答。
- 不良事件率35%,11.67%停药,其中8.3%因瘙痒停药。
关键数值与推荐
- 入组标准为不符合Paris II标准的PBC患者。
- 疗效评估采用GLOBE和UK-PBC评分从基线的变化,治疗12个月后评估POISE和Paris II标准。
- 肝纤维化通过FIB-4和AST/血小板比值指数(APRI)评估。
临床怎么用
- 对于UDCA应答不佳的PBC患者,OCA治疗可显著改善GLOBE预后评分和碱性磷酸酶,且肝纤维化指标保持稳定。
- 需关注不良事件,尤其是瘙痒导致的停药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obeticholic acid (OCA) was recently approved as the only on-label alternative for patients with primary biliary cholangitis (PBC) with intolerance or suboptimal response to ursodeoxycholic acid (UDCA). However, few data are available outside clinical trials. AIM: To assess the effectiveness and safety of OCA in a real-world cohort of patients with non-effective UDCA therapy. METHODS: Open-label, prospective, real-world, multicentre study, enrolling consecutive patients who did not meet Paris II criteria, from 18 institutions in Spain and Portugal. Effectiveness was assessed by the changes in GLOBE and UK-PBC scores from baseline. POISE and Paris II criteria were evaluated after 12 months of OCA . Liver fibrosis was evaluated by FIB-4 and AST to platelet ratio index (APRI). RESULTS: One hundred and twenty patients were eligible, median time since PBC diagnosis 9.3 (4.0-13.8) years, 21.7% had cirrhosis, and 26.7% received had previous or concomitant treatment with fibrates. Seventy-eight patients completed at least 1 year of OCA. The Globe-PBC score decreased to 0.17 (95% CI 0.05 to 0.28; P = 0.005) and the UK-PBC score decreased to 0.81 (95% CI -0.19 to 1.80; P = 0.11). There was a significant decrease in alkaline phosphatase of 81.3 U/L (95% CI 42.5 to 120; P < 0.001), ALT 22.1 U/L (95% CI 10.4 to 33.8; P < 0.001) and bilirubin 0.12 mg/dL (95% CI 0 to 0.24; P = 0.044). FIB-4 and APRI remained stable. According to the POISE criteria, 29.5% (23 out of 78) achieved response. The adverse events rate was 35%; 11.67% discontinued (8.3% due to pruritus). CONCLUSIONS: This study supports data from phase III trials with significant improvement of PBC-Globe continuous prognostic marker score among OCA-treated patients with good tolerability.
引用
- Gomez E, Garcia Buey L, Molina E, et al. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2020. PMID: 33314220. doi:10.1111/apt.16181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。